NATCO Pharma Ltd announces conclusion of USFDA inspection at Pharma Division, Kothur

NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced conclusion of US FDA Inspection at our Pharma Division located at Kothur, Hyderabad.

The U.S. Food and Drug Administration (FDA) had conducted an inspection at our Pharma Division located in Kothur, Hyderabad, India, which was conducted from June 9th - June 19th, 2025.

On conclusion of the inspection, the Company received 7 (Seven) observations in the Form-483. The Company is confident it will address the observations within the stipulated timeline. Company remains committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 881.35 as compared to the previous close of Rs. 877.60. The total number of shares traded during the day was 18569 in over 1061 trades.

The stock hit an intraday high of Rs. 886.50 and intraday low of 861.15. The net turnover during the day was Rs. 16260753.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 USFDA Inspection Conclusion PharmaDivision Kothur